Management of Advanced EGFR-Mutant Non-Small-Cell Lung Cancer Across the Disease Course

Advances in targeted therapy have improved outcomes for patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Third-generation EGFR tyrosine kinase inhibitors and first-line combination regimens have expanded treatment options, making the balance between survival benefit, toxicity, treatment burden, and individual patient fitness increasingly important in initial treatment selection. As acquired resistance continues to limit the duration of benefit, this decision must also be considered in the context of subsequent care. At progression, tissue and plasma profiling provide complementary information that can help characterize the diverse mechanisms of resistance and guide further treatment. As resistance-directed therapies and antibody-drug conjugates expand the available treatment options, their selection requires consideration of prior therapy and the pattern of progression, together with molecular findings where relevant. This review examines these interconnected decisions across the course of advanced EGFR-mutant NSCLC, from first-line treatment selection to the assessment and management of acquired resistance. We also address central nervous system involvement, uncommon EGFR mutations, and exon 20 insertions as distinct clinical settings in which disease distribution and the underlying molecular alteration shape treatment choices. By integrating clinical and translational evidence, we discuss how these factors may inform treatment sequencing and individualized care, with attention to survival, quality of life, and the cumulative burden of therapy across the disease course.

Authors

Institutions

Publication Details

Journal
Cancer Research and Treatment
Published
2026-11-16
DOI
https://doi.org/10.4143/crt.2026.1100
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Management of Advanced EGFR-Mutant Non-Small-Cell Lung Cancer Across the Disease Course

Geun‐Ho Park, Cheolyong Joe, Se-Hoon Lee, Hyemin Kim
1 links
Cancer Research and Treatment
Lung Cancer Treatments and Mutations
article

Management of Advanced EGFR-Mutant Non-Small-Cell Lung Cancer Across the Disease Course

Geun‐Ho Park, Cheolyong Joe, Se-Hoon Lee, Hyemin Kim
article en

Abstract

Advances in targeted therapy have improved outcomes for patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Third-generation EGFR tyrosine kinase inhibitors and first-line combination regimens have expanded treatment options, making the balance between survival benefit, toxicity, treatment burden, and individual patient fitness increasingly important in initial treatment selection. As acquired resistance continues to limit the duration of benefit, this decision must also be considered in the context of subsequent care. At progression, tissue and plasma profiling provide complementary information that can help characterize the diverse mechanisms of resistance and guide further treatment. As resistance-directed therapies and antibody-drug conjugates expand the available treatment options, their selection requires consideration of prior therapy and the pattern of progression, together with molecular findings where relevant. This review examines these interconnected decisions across the course of advanced EGFR-mutant NSCLC, from first-line treatment selection to the assessment and management of acquired resistance. We also address central nervous system involvement, uncommon EGFR mutations, and exon 20 insertions as distinct clinical settings in which disease distribution and the underlying molecular alteration shape treatment choices. By integrating clinical and translational evidence, we discuss how these factors may inform treatment sequencing and individualized care, with attention to survival, quality of life, and the cumulative burden of therapy across the disease course.

Cancer Research and Treatment
Samsung Medical Center (KR), Sungkyunkwan University (KR)
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon